Slide 1: Orion Financial Review 1/1/2016-12/31/2016
Orion Financial Review 1/1/2016-12/31/2016
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Another strong year for hundred-year-old Orion
Another strong year for hundred-year-old Orion ● Sales grew in largest business divisions 2015 2016 ● Operating profit boosted by EUR 22 million capital gains 1,074 1,016 ● Marketing authorisation for Easyhaler budesonide-formoterol combined formulation in Germany, United Kingdom and France ● Good t
Slide 4: Geographical breakdown of net sales
Geographical breakdown of net sales By market area Orion’s sales network 13% Finland 32% 8% Scandinavia Other Europe North America ROW 31% 16% 4 8 February 2017 Orion Financial Review 1/1/2016-12/31/2016 © Orion Corporation
Slide 5: Breakdown of net sales by business division
Breakdown of net sales by business division 2016 2015 Proprietary Products Specialty Products 508 471 +8% 4% 5% 4% Proprietary Products 350 323 +9% Specialty Products Animal Health 77 77 +0% 7% 33% Animal Health Fermion 48 53 -10% Fermion Contract Manufacturing Contract Manufacturing & other 39 38 +
Slide 6: Pharmaceuticals business
Pharmaceuticals business 6 8 February 2017 Orion Financial Review 1/1/2016-12/31/2016 © Orion Corporation
Slide 7: Best-selling pharmaceuticals 2016
Best-selling pharmaceuticals 2016 Net sales Change Product Indication EUR million vs. 2015 1. Parkinson’s disease 124 -10% 2. Asthma, COPD 64 +24% 3. Intensive care sedative 57 +28% 4. Acute decompensated heart failure 56 +10% Rheumatoid arthritis, inflammatory 5. bowel diseases 42 +51% 6. Animal se
Slide 8: Proprietary Products
Proprietary Products Breakdown of net sales ● Decline in sales of Stalevo, Comtess and Comtan slower than expected Stalevo, Comtess ● Easyhaler product family, Dexdor and Simdax 8% & Comtan grew strongly 6% Easyhaler ● Budesonide-formoterol Easyhaler received 35% Dexdor marketing authorisation in Ge
Slide 9: Parkinson's drugs
Parkinson’s drugs 60 Sales of Orion’s branded Parkinson drugs by market area MAT9/2016* 50 3% EUR million 40 30 20 26% Europe 10 45% Japan 0 ROW Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4 USA 2013 2014 2015 2016 26% Orion sales Deliveries to Novartis *Source: IMS Health sales statistics MAT9/2016 9 8 February
Slide 10: Easyhaler product family
Easyhaler product family ● Total Easyhaler product family sales grew by 24% 18 16 ● Bufomix Easyhaler sales grew by 68% 14 ● Sales of other products grew by 4% EUR million 12 10 ● Orion and Menarini commenced collaboration in 8 marketing budesonide-formoterol Easyhaler® 6 combined formulation 4 ● Or
Slide 11: Dexdor intensive care sedative
Dexdor intensive care sedative Dexdor sales European sedative market MAT9/2016* Total market value EUR 527 million (+2%) 18 16 14 14% EUR million 12 10 8% 8 66% 12% 6 4 2 0 Propofol EUR 347 million (+1%) Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4 Midazolam EUR 71 million (-6%) Dexmedetomidine EUR 44 million (
Slide 12: Specialty Products
Specialty Products growing in most important markets Net sales in key markets 2016 Breakdown of net sales EUR million vs. 2015 13% Finland Finland 300 +9% Scandinavia 82 +10% 12% Scandinavia Eastern Europe and Russia 59 +11% 16% 59% Eastern Europe & • At beginning of current year price band for Russ
Slide 13: Orion strong in home market Finland
Orion strong in home market Finland Finland’s biggest pharmaceutical Finnish human pharmaceuticals market 2016 companies in 2016 ● Wholesale EUR 2,320 million 350 299 300 ● Growth of total market +4% EUR million 250 ● Orion's market share 13% 200 157 ● Orion's growth +11% 150 102 105 122 100 50 0 13
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Easyhaler® budesonide-formoterol Asthma, COPD BEq study 1) Registration2) Easyhaler® salmeterol-fluticasone Asthma, COPD BEq study 1) ODM-201 (androgen receptor antagonist) 3) Prostate cancer (nmCRPC) I II III
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-109 (oral levosimendan) ALS I II ORM-12741 (alpha-2c adrenoceptor antagonist) 5) Alzheimer’s disease I IIa ODM-104 (more effective COMT inhibitor) Parkinson’s disease I II ODM-203 (targeted FGFR+VEGFR inhi
Slide 16: Diagnostics business
Diagnostics business 16 8 February 2017 Orion Financial Review 1/1/2016-12/31/2016 © Orion Corporation
Slide 17: Orion Diagnostica
Orion Diagnostica 2015 2016 ● QuikRead® tests remained the main product ● Launching of first Orion GenRead® test system 58 55 products continued ● Product family expanded late in the year with a Campylobacter test 8.5 8.4 Net sales, Operating profit, EUR million EUR million -5% 17 8 February 2017 Or
Slide 18: Outlook and financial objectives
Outlook and financial objectives 18 8 February 2017 Orion Financial Review 1/1/2016-12/31/2016 © Orion Corporation
Slide 19: Outlook for 2017
Outlook for 2017 Net sales are estimated to be at similar level to 2016 (net sales were EUR 1,074 Net sales million in 2016). Operating profit excluding material capital gains is estimated to be at least EUR Operating profit 280 million (operating profit excluding capital gains was EUR 293 million i
Slide 20: Orion's financial objectives
Orion’s financial objectives Growing net sales more rapidly than ≥ growth of the pharmaceuticals market. Achievement of this objective requires continuous investment in Keeping the equity ratio at least 50%. development of the product portfolio. Distributing an annual dividend that > Maintaining p
Slide 21: Orion Calendar
Orion Calendar Annual General Meeting 2017 Wednesday 22 March 2017 Interim Report January–March 2017 Wednesday 26 April 2017 Half-Year Financial Report January–June 2017 Wednesday 19 July 2017 Interim Report January–September 2017 Thursday 26 October 2017 The Financial Statements and Report by the B
Slide 22: SAVE THE DATE Capital Markets Day
SAVE THE DATE Capital Markets Day 18 May 2017 Helsinki Formal invitation and registration details will be provided at a later stage.
Slide 23: Building well-being. Together.
Building well-being. Together.